Diabetic Macular Edema – Epidemiology – Mature Markets
| DRG Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of DME for each country, as well as annualized case counts projected to the national population. |
| DRG Epidemiology’s DME forecast will answer the following questions: |
| How will changes in the levels of exposure to known risk or protective factors affect the number of people living with DME? |
| Of all people with DME, how many in each of the major mature pharmaceutical markets have been formally diagnosed? |
| Of all people diagnosed with DME, how many in each of the major mature pharmaceutical markets are drug-treated? |
| How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DME over the forecast period? |
| All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. |
| In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following DME subpopulations: |
| Diagnosis status. |
| Treatment status. |
| Note: Coverage may vary by country and region. |
| Source: Clarivate |
Table of contents
- Diabetic Macular Edema - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Total Prevalence of Diabetic Macular Edema per 1,000 People Aged 20+ in 2018 and 2028
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Diabetic Macular Edema over the Next Ten Yearstttttttt
- Analysis of Total Prevalent Cases of Diabetic Macular Edema in 2018 by Severity of Diabetic Retinopathy
- Epidemiology Data
- Methods
- Total Prevalent Cases of DME
- Total Prevalent Cases of DME by DR Severity
- Diagnosed Prevalent Cases of DME
- Drug-treated Prevalent Cases of DME
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Diabetic Macular Edema
- Studies Excluded from the Analysis of Diabetic Macular Edema
- Risk/Protective Factors
- Risk/Protective Factors for Diabetic Macular Edema
- Bibliography
- Literature Review
- Introduction
Fjoralba Kristo, M.D., M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she completed a postdoctoral fellowship at the University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as a research scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Dr. Kristo holds an M.P.H. degree from Boston University School of Public Health, with a concentration in epidemiology and biostatistics, and a medical degree from the University of Medicine in Bucharest, Romania.
Nicole Zhang, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she worked as a research analyst at Massachusetts General Hospital, where she independently managed data from a food information survey conducted in Chelsea, Massachusetts. She has also worked for the Massachusetts Department of Public Health, conducting secondary research in the field of gestational diabetes. She holds an M.P.H. from Tufts Medical School, where she specialized in epidemiology and biostatistics. She also holds a B.A. in chemistry and statistics from Mount Holyoke College.